


AstraZeneca Docket No. A2090-1P US

Application No. 09/529,654

Page 3IN THE CLAIMS:

Please CANCEL all existing claims and ENTER new claims 44 to 56 inclusive, as follows:

44.(New) A compound of formula I,



wherein

NRR^1 is attached at the 5- or 6-position of the furopyridine ring;

R is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or COR^2 ;

R^1 is $(\text{CH}_2)_n\text{Ar}$, $\text{CH}_2\text{CH}=\text{CHAr}$, or $\text{CH}_2\text{C}=\text{CAr}$;

n is 0 to 3;

A is N;

Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or:

Ar is an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; any of which may optionally be substituted with one to two substituents independently selected from: halogen, trifluoromethyl, or $\text{C}_1\text{-C}_4$ alkyl;

R^2 is hydrogen, $\text{C}_1\text{-C}_4$ alkyl; $\text{C}_1\text{-C}_4$ alkoxy; or a phenyl ring optionally substituted with one to three of the following substituents: halogen, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_2\text{-C}_4$ alkenyl, $\text{C}_2\text{-C}_4$ alkynyl, OH, $\text{OC}_1\text{-C}_4$ alkyl, CO_2R^5 , $-\text{CN}$, $-\text{NO}_2$, $-\text{NR}^3\text{R}^4$, or $-\text{CF}_3$;

AstraZeneca Docket No. A2090-11 US
Application No. 09/529,654
Page 4

*El
Contd*

R^3 , R^4 and R^5 are independently hydrogen; C_1 - C_4 alkyl; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_2 - C_4 alkynyl, OH, OC_1 - C_4 alkyl, -CN; -NO₂, or -CF₃; or an enantiomer thereof, and pharmaceutically acceptable salts thereof, with the proviso that said compound is not 5'-N-benzylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine].

45.(New) A compound according to claim 44, wherein R_1 is $CH_2CH=CHAr$; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

46.(New) A compound according to claim 44, wherein R_1 is $CH_2C\equiv CAr$; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

47.(New) A compound according to claim 44, wherein R_1 is $(CH_2)_nAr$; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

48.(New) A compound according to claim 44, wherein Ar is selected from the group: 1-, or 2-naphthyl; 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl; 2-, 4-, 5-, 6-, or 7-benzoxazolyl; and 3-, 4-, 5-, 6-, or 7-benzisoxazolyl; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

49.(New) A compound according to claim 44, wherein R^3 , R^4 and R^5 are independently hydrogen, or C_1 - C_4 alkyl; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

50.(New) A compound according to claim 44, wherein Ar is an heteroaromatic ring.

AstraZeneca Docket N . A2090-1P US

Application No. 09/529,654

Page 5

51.(New) A compound according to claim 44, wherein n is 1.

52.(New) A compound according to any one of claim 51, wherein R is hydrogen and Ar is an heteroaromatic ring.

53.(New) A compound according to claim 44, wherein R is hydrogen.

54. (New) A compound according to claim 44, said compound being:

R-(-)-5'-(3-pyridylmethyl) aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine], or

R-(-)-5'-(4-pyridylmethyl) aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

55.(New) A compound according to claim 44, said compound being:

R-(-)-5'-(2-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(3-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(4-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(2-furanylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(3-furanylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(2-thienylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

AstraZeneca Docket No. A2090-1P US

Application No. 09/529,654

Page 6

R-(-)-5'-(2-imidazolylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(4-methoxyphenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(4-chlorophenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(4-methylphenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3,4-dichlorophenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-acetyl-N-(phenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-methyl-N-(phenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

(R)-(-)-5'-N-(3-pyridyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

(R)-(-)-6'-N-(phenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3-thienylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(2-phenylethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3-phenylpropyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(quinolin-3-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(quinolin-4-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

AstraZeneca Docket No. A2090-1P US

Application No. 09/529,654

Page 7

R-(-)-5'-N-(1,4-benzodioxan-6-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(imidazol-4-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(*trans*-3-phenylprop-2-enyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(thiazol-2-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3-methylphenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(2-chlorophenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3-chlorophenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3-phenylpropynyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3-hydroxyphenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(4-hydroxyphenylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-[*trans*-3-(4-pyridinyl)prop-2-enyl]aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-acetyl-N-(3-thienylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];


R-(-)-5'-N-methyl-N-(4-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-methyl-N-(3-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine], or

AstraZeneca Docket No. A2090-1P US

Application No. 09/529,654

Page 8

 R-(-)-5'-N-(2-hydroxyethyl)-N-(3-thienylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

56.(New) A pharmaceutical composition comprising a compound according to claim 44, in admixture with an inert pharmaceutically acceptable diluent or carrier.
